What's Next For Artificial Intelligence In The Clinic?
Executive Summary
Numerate CEO Guido Lanza talks to Scrip about how artificial Intelligence, or AI, has been quietly used by some drug developers for the last decade, but its use is now rocketing. Also, what is next for AI in pharma?
You may also be interested in...
Who's Who In Artificial Intelligence Drug Development
Artificial intelligence companies focused on the life science sector have boomed in the past decade. Many of these firms are working with pharma partners and a small number are pursuing their own drug development pipelines.
AstraZeneca Signs AI Deal To Pursue Novel Parkinson's Drugs
AstraZeneca is the most recent big pharma to team up with an artificial intelligence business – following in the footsteps of Takeda, Johnson & Johnson, Sanofi and GlaxoSmithKline – having signed a drug discovery deal with Boston-based BERG.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.